One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo
in Patients after Acute Myocardial Infarction
and Left Ventricular Dysfunction.
Bone Marrow Res. 2011 ;2011:385124. Epub 2011 Feb 27. PMID: 22046562
Samer Mansour, Denis-Claude Roy, Vincent Bouchard, Louis Mathieu Stevens, Francois Gobeil, Alain Rivard, Guy Leclerc, François Reeves, Nicolas Noiseux
Division de Cardiologie, Département de Médecine, Centre Hospitalier de l'Université de Montréal (CHUM), 3840, Rue Saint Urbain, Montréal, Québec, Canada H2W 1T8.
Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133(+) hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the initial 20 patients enrolled in the COMPARE-AMI trial, the first double-blind randomized controlled trial comparing the safety, efficacy, and functional effect of intracoronary injection of selected CD133(+) cells to placebo
following acute myocardial infarction
with persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial infarction
, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction significantly improved at four months as compared to baseline and remained significantly higher at one year. These data indicate that in the setting of the COMPARE-AMI trial, the intracoronary injection of selected CD133(+) stem cells is secure and feasible in patients with left ventricle dysfunction following acute myocardial infarction
Article Published Date : Jan 01, 2011